A "Win-win-win" Situation: Nanotechnology in Regenerative Medicine

bridges vol. 14, July 2007 / Nanotechnology Focus

{play}images/stories/mp3/vol14_stupp.mp3{/play}
{enclose vol14_stupp.mp3}

Samuel Stupp, director of the Institute for BioNanotechnology in Medicine at Northwestern University, is at the center of cutting-edge medical research that has the potential to tackle challenges like Alzheimer's, Parkinson's, heart attacks, and spinal cord injuries.

In Stupp's opinion, the keys to these yet-unsolved problems are nanotechnology and regenerative medicine. In one of Stupp's experiments, lab mice with severed spinal cords regained partial function in their hind legs. The question is: Can these results eventually be translated to humans?

Professor Stupp - according to Scientific American one of the "50 Leaders Shaping the Future of Technology for 2005," and one of the "15 Scientists That Will Change Your World" (Biotechnology Industrial Organization) - wants to find out. Among his numerous society and board memberships, he is also connected to Austria as a member of the University of Vienna Scientific Advisory Board.

In the following interview with bridges, Stupp provides insight into the stunning prospects of his cutting-edge research, addresses the controversial legal framework of research in regenerative medicine, and comments on the allegations of potential dangers of his research.

Access to the full article is free, but requires you to register. Registration is simple and quick - all we need is your name and a valid e-mail address. We appreciate your interest in bridges.